pf-06946860
mAbexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jul 30, 2018 (NCT03599063)
Timeline
Indications
Studied for
- Anorexia · Phase 1
- Appetite · Phase 2
- Breast Neoplasms · Phase 1
- Cachexia · Phase 2/Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colorectal Neoplasms · Phase 2
- Fatigue · Phase 2
- Healthy Volunteers · Phase 1
- Heart Failure · Phase 2
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 2/Phase 3
- Prostatic Neoplasms · Phase 1
Mechanism of action
- Growth/differentiation factor 15INHIBITOR
GDF15 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650502 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06989437 | Phase 2/Phase 3 (Phase 3) | Oct 3, 2025 | Pfizer |
| NCT05685264 | Phase 1 | Jan 18, 2023 | Pfizer |
| NCT05546476 | Phase 2 | Nov 21, 2022 | Pfizer |
| NCT05492500 | Phase 2 | Sep 26, 2022 | Pfizer, The TIMI Study Group |
| NCT04803305 | Phase 1 | May 11, 2021 | Pfizer |
| NCT04299048 | Phase 1 | Apr 30, 2020 | Pfizer |
| NCT03974776 | Phase 1 | Jun 10, 2019 | Pfizer |
| NCT03599063 | Phase 1 | Jul 30, 2018 | Pfizer |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 8 | 8 | 3 | 2018 |
| The TIMI Study Group | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1